Navigation Links
Xencor Initiates Phase 1 Study of XmAb®5871 Therapeutic Antibody for the Treatment of Autoimmune Diseases
Date:10/21/2011

MONROVIA, Calif., Oct. 21, 2011 /PRNewswire/ -- Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, announced today the initiation of a Phase 1 clinical trial of XmAb®5871, the company's therapeutic antibody for the treatment of autoimmune diseases. XmAb5871 uses a novel dual-targeted approach to potently suppress autoimmune disorders that may avoid some of the side effects seen with other therapeutic antibodies that modulate immune response. The advancement of XmAb5871 into clinical stage testing demonstrates the broad potential of Xencor's antibody engineering technology in immune and inflammatory diseases in addition to oncology.

Earlier this year, Amgen and Xencor entered into an option agreement to develop XmAb5871. Under the terms of the agreement, Amgen has the option to an exclusive worldwide license following the completion of a pre-defined Phase 2 study. Xencor will lead all clinical development until that time.

"XmAb5871 is Xencor's first therapeutic antibody for immune disorders, and is the fifth XmAb product to enter clinical testing," said Bassil Dahiyat, Ph.D., president and CEO of Xencor. "Xencor's robust product pipeline in oncology, and now autoimmune disease, is evidence of the broad applicability of our XmAb technology across multiple therapeutic areas."

XmAb5871 is a humanized monoclonal antibody that uses a uniquely selective dual-targeting mechanism for B cell inhibition by targeting the antigen CD19 and co-engaging CD32b (FcγRIIb), thereby suppressing autoimmune response. Preclinical studies published in the Journal of Immunology showed that XmAb5871 potently suppresses autoimmune response in humanized mouse models of systemic lupus erythematosus (SLE), without the depletion of B cells. This suggests that XmAb5871 may be an effective immunosuppressant in multiple indications, including SLE and rheumatoid arthrit
'/>"/>

SOURCE Xencor, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Finland initiates European biomedical research infrastructures construction with $6.7 million for 2011
2. Rosetta Genomics Initiates Closing of Private Placement
3. Phase III data show efficacy/safety of iclaprim in patients with complicated skin infections
4. Positive results in Phase 2 trial of treatment of C-difficile-associated diarrhea
5. NIH grants Phylonix Phase II SBIR to develop high-throughput in vivo zebrafish assays
6. Biolex presents Locteron US Phase 2a hepatitis C data at EASL
7. Cantabrian cornice has experienced seven cooling and warming phases over past 41,000 years
8. Resolvyx announces positive data -- Phase 2 trial of resolvin RX-10045 for dry eye syndrome
9. Scientists seek new emphases in Arctic climate change research
10. NIH funds new phase of high school-university research partnership
11. Registration Opens for Next Testing Phase of IEEE Certified Biometrics Professional Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... starting March 30 th . The ... New York markets. Gino ... our new ad campaign following the recent initial shipment of ...
(Date:3/19/2015)... March 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... clip that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host ... way to pay, and ,a really big breakthrough in mobile ...
(Date:3/16/2015)... Germany , March 16, 2015 ... Identification Systems GmbH will present groundbreaking innovations in ... Hanover, Germany .      ... DERMALOG,s latest biometric innovation is well at the ... next generation e-gate made in Germany ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... increased by an unprecedented 11cm between the mid-nineteenth century ... today in the journal Oxford Economic Papers . ... height actually accelerated in the period spanning the two ... Hatton, Professor of Economics at the University of Essex ...
... watched as strain after strain of the deadly bacteria ... the last few decades researchers have used the tools of ... allow TB to withstand many of the key therapeutics that ... clues for new drug development and as tools for diagnosing ...
... 31, 2013 Amgen (NASDAQ: AMGN ) today ... low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, of up to ... four 12-week Phase 2 studies evaluating AMG 145 in patient ... monoclonal antibody that inhibits PCSK9, a protein that reduces the ...
Cached Biology News:New data reveals that the average height of European males has grown by 11cm in just over a century 2Researchers untangle genetics of drug resistant TB 2Researchers untangle genetics of drug resistant TB 3Researchers untangle genetics of drug resistant TB 4Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients 2Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients 3Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients 4Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients 5Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients 6Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients 7Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients 8
(Date:3/29/2015)... March 29, 2015  Caris Life Sciences® today ... Caris Molecular Intelligence®, the company,s panomic, comprehensive tumor ... between several rare and difficult to treat gynecological ... the potential to improve patient outcomes. These studies ... the Society of Gynecologic Oncology (SGO) 2015 Annual ...
(Date:3/29/2015)... As a symbol of its commitment to meet ... clients, Whitehouse Laboratories is excited to announce that is ... for the 2015 race season. Success on the race ... sense of precision and attention to detail. These are ... quality control testing laboratory. Sponsorship of the race car, ...
(Date:3/27/2015)... , 27. März 2015  Peter Walter ... Biomedical Science für seine bahnbrechende Arbeit ausgewählt, ... Zellkompartimenten transportiert werden, sowie für die Entschlüsselung ... Reaktion auf Stress nutzen, der mit der ... ist Professor für Biochemie an der University ...
(Date:3/27/2015)... March 27, 2015  Peter Walter was chosen as ... his pioneering work on how proteins are transported between ... regulatory mechanism that cells use to handle stress tied ... a professor of biochemistry at the University of California, ... a range of human diseases related to defective protein ...
Breaking Biology Technology:Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3
... A tiny grid pattern has led materials scientists at ... the Institute of Solid State Physics in Russia to ... certain electromagnetic nanostructures used in data storage. Their recently ... design and manufacture of future ultra-high density data storage ...
... , SAN DIEGO, July 1 Biocept, Inc. ("Biocept"), an emerging ... and M. Faye Wilson as Directors. , , "We ... experience will be invaluable to us as we move into our ... , , Ms. Wilson has been a principal of ...
... Morphotek(R), Inc., a subsidiary of Eisai Corporation of North ... Corporation to express and develop therapeutic monoclonal antibodies for ... infectious disease. , , Under the terms of ... Platform (SEP(TM)) technology and its expertise to produce and ...
Cached Biology Technology:Unexpectedly long-range effects in advanced magnetic devices 2Biocept, Inc. Announces Two New Director Appointments 2Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease 2Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease 3
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
...
...
...
Biology Products: